Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Minimally Invasive Surgery for Endometrial Cancer

Obstet Gynecol; ePub 2018 Jan 9; Casarin, et al

In women treated for endometrial cancer in the US, minimally invasive surgery is associated with substantial decreases in 30-day morbidity, readmission, and reoperation. This according to a retrospective cohort study that compared 30-day surgical outcomes between 12,283 patients who had minimally invasive surgery and open surgery from 2008 to 2014. Researchers found:

  • During the study period, a significant implementation of minimally invasive surgery (24.2% to 71.4%) and a concomitant decrease in open surgery through laparotomy were observed.
  • Rate of vaginal surgery did not change over time.
  • After adjusting for possible confounders, open surgery (vs minimally invasive surgery) was independently associated with increased odds of major complications, readmission, reoperation, superficial surgical site infection, perioperative transfusion, and death.
  • There was a comprehensive decrease in 30-day morbidity for the treatment of endometrial cancer overall; 30-day mortality remained unchanged.


Casarin J, Multinu F, Ubl D, et al. Adoption of minimally invasive surgery and decreased in surgical morbidity for endometrial cancer treatment in the United States. [Published online ahead of print January 9, 2018]. Obstet Gynecol. doi:10.1097/AOG.0000000000002428.